Cardiovascular Adverse Events in Modern Myeloma Therapy - Incidence and Risks. A Review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Overview

Journal Haematologica

Specialty Hematology

Date 2018 Jul 28

PMID 30049825

Citations 45

Authors

Sara Bringhen

Alberto Milan

Claudio Ferri

Ralph Wasch

Francesca Gay

Alessandra Larocca

Marco Salvini

Evangelos Terpos

Hartmut Goldschmidt

Michele Cavo

Maria Teresa Petrucci

Heinz Ludwig

Holger W Auner

Jo Caers

Martin Gramatzki

Mario Boccadoro

Hermann Einsele

Pieter Sonneveld

Monika Engelhardt

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal dysfunction) and/or related to anti-myeloma treatment (anthracyclines, corticosteroids, alkylating agents, immunomodulatory drugs, proteasome inhibitors). Good knowledge of cardiovascular events, effective dose reductions, prevention and management of early and late cardiovascular side effects of chemotherapeutic agents are essential in current clinical practice. Myeloma experts are obliged to carefully balance the efficacy and toxicity of drugs for each individual patient. This review summarizes current data and novel insights into cardiovascular adverse events of today's anti-myeloma treatment, focusing on carfilzomib, as a starting point for developing consensus recommendations on preventing and managing cardiovascular side effects in patients with multiple myeloma.

Citing Articles

Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma.

Fanelli E, Picca G, Airale L, Astarita A, Mingrone G, Catarinella C Hypertens Res. 2025; .

PMID: 39843857 DOI: 10.1038/s41440-024-02084-w.

Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma.

Tantawy M, Langaee T, Wang D, Rubinstein S, Cornell R, Lenihan D Int J Mol Sci. 2024; 25(14).

PMID: 39063038 PMC: 11276722. DOI: 10.3390/ijms25147795.

Major cardiovascular events in long-term multiple myeloma survivors: a Korean case-control study (the CAREMM-2105 study).

Ha J, Choi S, Moon S, Han J, Lee J, Baek K Clin Exp Med. 2024; 24(1):125.

PMID: 38864999 PMC: 11169014. DOI: 10.1007/s10238-024-01368-2.

Cyclophosphamide, Bortezomib, and Dexamethasone and Severe Systolic Heart Failure: A Case Report.

Pandey S, Tan E, Bellamkonda A, Aryal B, Kalavar M Cureus. 2024; 16(3):e56966.

PMID: 38665754 PMC: 11044976. DOI: 10.7759/cureus.56966.

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.

Geraldes C, Roque A, Sarmento-Ribeiro A, Neves M, Ionita A, Gerivaz R Front Oncol. 2024; 14:1282300.

PMID: 38585008 PMC: 10995327. DOI: 10.3389/fonc.2024.1282300.

References

Dimopoulos M, Eleutherakis-Papaiakovou V . Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med. 2004; 117(7):508-15. DOI: 10.1016/j.amjmed.2004.03.040. View

Voortman J, Giaccone G . Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006; 6:129. PMC: 1475607. DOI: 10.1186/1471-2407-6-129. View

Palumbo A, Rajkumar S, Dimopoulos M, Richardson P, San Miguel J, Barlogie B . Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2007; 22(2):414-23. DOI: 10.1038/sj.leu.2405062. View

Hacihanefioglu A, Tarkun P, Gonullu E . Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol. 2008; 88(2):219-222. DOI: 10.1007/s12185-008-0139-7. View

Yeh E, Bickford C . Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009; 53(24):2231-47. DOI: 10.1016/j.jacc.2009.02.050. View

Foley P, Hamilton M, Leyva F . Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. J Cardiovasc Med (Hagerstown). 2009; 11(5):386-8. DOI: 10.2459/JCM.0b013e32832f3ff2. View

Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S . Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol. 2010; 91(5):903-6. DOI: 10.1007/s12185-010-0586-9. View

Nowis D, Maczewski M, Mackiewicz U, Kujawa M, Ratajska A, Wieckowski M . Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol. 2010; 176(6):2658-68. PMC: 2877829. DOI: 10.2353/ajpath.2010.090690. View

Hong R, Iimura T, Sumida K, Eager R . Cardio-oncology/onco-cardiology. Clin Cardiol. 2010; 33(12):733-7. PMC: 6653579. DOI: 10.1002/clc.20823. View

10.

Carrier M, Le Gal G, Tay J, Wu C, Lee A . Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 2011; 9(4):653-63. DOI: 10.1111/j.1538-7836.2011.04215.x. View

11.

Moreau P, Richardson P, Cavo M, Orlowski R, San Miguel J, Palumbo A . Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012; 120(5):947-59. PMC: 4123429. DOI: 10.1182/blood-2012-04-403733. View

12.

Jakubowiak A, Dytfeld D, Griffith K, Lebovic D, Vesole D, Jagannath S . A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012; 120(9):1801-9. PMC: 5162553. DOI: 10.1182/blood-2012-04-422683. View

13.

Kortuem K, Stewart A . Carfilzomib. Blood. 2013; 121(6):893-7. DOI: 10.1182/blood-2012-10-459883. View

14.

Sheppard R, Berger J, Sebag I . Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy. Front Pharmacol. 2013; 4:19. PMC: 3594741. DOI: 10.3389/fphar.2013.00019. View

15.

Siegel D, Martin T, Nooka A, Harvey R, Vij R, Niesvizky R . Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013; 98(11):1753-61. PMC: 3815177. DOI: 10.3324/haematol.2013.089334. View

16.

Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M . Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi133-7. DOI: 10.1093/annonc/mdt297. View

17.

Xiao Y, Yin J, Wei J, Shang Z . Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One. 2014; 9(1):e87671. PMC: 3906186. DOI: 10.1371/journal.pone.0087671. View

18.

Dimopoulos M, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M . Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014; 28(8):1573-85. PMC: 4131249. DOI: 10.1038/leu.2014.60. View

19.

Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S . Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014; 18(6):947-61. PMC: 4508135. DOI: 10.1111/jcmm.12279. View

20.

Bringhen S, Petrucci M, Larocca A, Conticello C, Rossi D, Magarotto V . Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014; 124(1):63-9. DOI: 10.1182/blood-2014-03-563759. View